Amgen Inc. AMGN
460.42 USD +0.14 (+0.03%)
At closeNov 9, 2026, 7:39 AM EST
463.72 +3.30 +0.72%
Pre-market · Nov 9, 7:39 AM ET
447.04 Day range 462.91
312.39 52-week range 483.99
- YTD
- +40.67%
- 1 year
- +45.89%
News
benzinga.com Freedom Broker Downgrades Amgen to Hold, Raises Price Target to $470 Freedom Broker analyst Ilya Zubkov downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and raises the price target from $450 to $470.
benzinga.com Leerink Partners Maintains Market Perform on Amgen, Raises Price Target to $464 Leerink Partners analyst David Risinger maintains Amgen (NASDAQ:AMGN) with a Market Perform and raises the price target from $395 to $464.
fool.com Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance…
benzinga.com Guggenheim Maintains Neutral on Amgen, Raises Price Target to $435 Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $378 to $435.
benzinga.com Amgen Announces Results From Large Real-World Study Showing Treatment With Repatha Reduced Risk Of Fatal Or Nonfatal Heart Attacks By 20% Compared With Ezetimibe In People With ASCVD And Prior Statin Use Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart DiseaseResults Provide…
prnewswire.com REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart Disease Results…
defenseworld.net 2,369 Shares of Amgen Inc. $AMGN Bought by First Nebraska Trust Co First Nebraska Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…- benzinga.com Canaccord Genuity Maintains Hold on Amgen, Raises Price Target to $440 Canaccord Genuity analyst Gary Nachman maintains Amgen (NASDAQ:AMGN) with a Hold and raises the price target from $384 to $440.
- benzinga.com Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $530 Scotiabank analyst Louise Chen maintains Amgen (NASDAQ:AMGN) with a Sector Outperform and raises the price target from $500 to $530.
- benzinga.com Citigroup Maintains Neutral on Amgen, Raises Price Target to $465 Citigroup analyst Geoff Meacham maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $405 to $465.
benzinga.com JP Morgan Maintains Neutral on Amgen, Raises Price Target to $425 JP Morgan analyst Chris Schott maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $350 to $425.
benzinga.com TD Cowen Maintains Buy on Amgen, Raises Price Target to $531 TD Cowen analyst Yaron Werber maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $452 to $531.
benzinga.com Goldman Sachs Maintains Buy on Amgen, Raises Price Target to $536 Goldman Sachs analyst Salveen Richter maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $481 to $536.
benzinga.com Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data Amgen Inc. (NASDAQ:AMGN) shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance.
benzinga.com Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data Amgen approaches 52-week highs on Q3 earnings beats and raised 2026 guidance, while Wall Street analysts lift price targets.
benzinga.com Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $410 Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $359 to $410.- benzinga.com RBC Capital Maintains Outperform on Amgen, Raises Price Target to $470 RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $430 to $470.
zacks.com AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook Amgen raises its 2026 outlook after Q3 earnings and revenue beat estimates, as IMDELLTRA advances and MariTide offers potential long-term growth opportunities.- benzinga.com Truist Securities Maintains Hold on Amgen, Raises Price Target to $398 Truist Securities analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Hold and raises the price target from $380 to $398.
- benzinga.com Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $460 Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $430 to $460.
zacks.com AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.
benzinga.com $1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 2.06% on an annualized basis producing an average annual return of 14.83%. Currently, Amgen has a market capitalization of…
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Rise as Democrats Take Control of Congress—AMD, AMGN, NVO in Focus (UPDATED) U.S. stocks rose on Wednesday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures advanced, following Tuesday's mixed close.
benzinga.com Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $465 Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $440 to $465.
seekingalpha.com Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript
marketbeat.com What Amgen (AMGN) Said on Its Q3 Earnings Call Amgen NASDAQ: AMGN reported third-quarter revenue growth of 8% year over year to $10.4 billion, supported by broad-based demand across its portfolio and continued clinical progress in several…
zacks.com Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates Amgen (AMGN) came out with quarterly earnings of $6.45 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $5.64 per share a year ago.
benzinga.com Amgen Q3 2026 Earnings Call Transcript Amgen (NASDAQ:AMGN) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…- benzinga.com Amgen Raises FY2026 Adj EPS Guidance from $22.30-$23.50 to $22.90-$23.70 vs $23.02 Est; Raises FY2026 Sales Guidance from $38.200B-$39.400B to $38.900B-$39.700B vs $38.936B Est Amgen (NASDAQ:AMGN) raises FY2026 Adj EPS guidance from $22.30-$23.50 to $22.90-$23.70 vs $23.02 analyst estimate. Raises FY2026 sales outlook from $38.200 billion-$39.400 billion to $38.900…
- benzinga.com Amgen Raises FY2026 GAAP EPS Guidance from $15.80-$17.08 to $18.34-$19.28 vs $15.90 Est Amgen (NASDAQ:AMGN) raises FY2026 GAAP EPS guidance from $15.80-$17.08 to $18.34-$19.28 vs $15.90 analyst estimate..
prnewswire.com AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds dip to 45% as Wall Street navigates Election Day, AMD earnings, and a volatile oil market.
benzinga.com AMD, Shopify On Deck Tuesday As AI Spending, Merchant Growth Face Test Advanced Micro Devices headlines Tuesday’s reports, with investors looking for evidence that AI demand can withstand a sharp pullback in the stock. Shopify, Pfizer, Eaton, Marathon Petroleum and…
benzinga.com AMD Could Swing $90.7 Billion After Earnings Seven major companies are set to report earnings Tuesday, and options traders are pricing in significant stock moves. From Pfizer’s modest 4.14% implied move to Shopify’s 13.01% swing, here’s a…
zacks.com Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts? AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.
fool.com Amgen Just Gave Its Shareholders Great News Amgen's cancer drug Imdelltra has been shown to be effective in treating advanced lung cancer when paired with AstraZeneca's Imfinzi. The risk of death was cut by 58% for patients who used the…
benzinga.com Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer Reed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.
benzinga.com Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer Amgen's Imdelltra with Imfinzi cut small-cell lung cancer death risk by 58% in Phase 3, extending median survival to 21.1 months. Read more.- benzinga.com Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $480 Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $450 to $480.
- benzinga.com Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $400 Barclays analyst Emily Field maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $380 to $400.
benzinga.com AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.- benzinga.com Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and…
- benzinga.com AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs.…
benzinga.com Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Currently, Amgen has a market capitalization of…
benzinga.com Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.- benzinga.com Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378 Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.
- benzinga.com BMO Capital Maintains Market Perform on Amgen, Lowers Price Target to $415 BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Market Perform and lowers the price target from $450 to $415.
- benzinga.com Wells Fargo Maintains Equal-Weight on Amgen, Lowers Price Target to $430 Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $435 to $430.
- benzinga.com RBC Capital Maintains Outperform on Amgen, Raises Price Target to $430 RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $430.